Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISS-RESMEPO: Predictors of Long-Lasting Response to Mepolizumab in CRSwNP
NCT05902325Phase 4Active, not recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Persistent clinical response to mepolizumab after cessation off mepoluzimab treatment at 18 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05902325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902325.